• By ICR Secretariat
  • Posted Thursday, March 24, 2022

How Merck's 'puzzling' results could impact immunotherapy's role in early lung cancer

https://www.biopharmadive.com/news/merck-keytruda-early-lung-cancer-results-opdivo-tecentriq/620543/

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study supporting its benefit add to questions about the best way to use it.